cytisine

(redirected from Tabex)
Also found in: Dictionary.

cy·ti·sine

(sit'ĭ-sin),
A toxic selective nicotinic cholinergic agonist; an alkaloid from the seed of Laburnum anagyroides and other Leguminosae. Used in pharmacologic studies of nicotinic cholinergic receptors in the brain.
Synonym(s): baptitoxine

cytisine

the toxic quinolizidine alkaloid in laburnum (Laburnum anagyroides), Retama retam and broom (Cytisus scoparius) trees.
References in periodicals archive ?
4% of those given Tabex were able to avoid smoking for a year compared with just 2.
Professor Robert West, from the Cancer Research UK Health Behaviour Research Centre at University College London, said he expects to see a flood of internet orders for Tabex once the drug is publicised.
4 times more likely to stop smoking with Tabex than with a "dummy" placebo tablet.
4 percent of those given Tabex were able to avoid smoking for a year compared with 2.
In order to distribute Tabex in the US, the company needs the approval of the most stringent drug regulator in the world, the Food and Drug Administration (FDA).
001) indicating that smokers treated with Tabex were 3.
Moreover, extensive evaluation of the Tabex safety database shows no evidence of significant neuropsychiatric or behavioural side-effects as seen with some currently marketed smoking cessation drugs.
According to the study, Tabex (cytisine), which has been used in Central and Eastern European countries for many years, would increase each year of life at a cost of about $300, compared to current National Health Service (United Kingdom) medicines' cost which are approximately $3,0001.
It follows recent publication of a trial showing Tabex to be effective in helping people stop smoking2.
Professor Robert West, Department of Epidemiology and Public Health at University College London and Principal Investigator on the TASC trial, concluded, "With more than a billion smokers worldwide and lung cancer still as one of the top killers, the results of the TASC trial and these cost effectiveness data show that not only is Tabex comparable with market leading smoking cessation treatments, but that its cost effectiveness has the capacity to save millions of lives globally, by providing an affordable and effective treatment to help people stop smoking.
The TASC trial and these new cost effectiveness results show that Tabex has a greater potential than existing treatments to save millions of lives globally.
Over 20 million patients have been treated with Tabex and the latest Periodic Safety Update Reports (PSUR) submitted to the European Medicines Evaluation Agency (EMEA) was based on approximately 8 million cases.